Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
60
LDXHF Quote, Financials, Valuation and Earnings
Last price:
$0.1700
Seasonality move
:
47.73%
Day range:
$0.1700 - $0.1700
52-week range:
$0.0100 - $0.2093
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.33x
P/B ratio:
4.40x
Volume:
5K
Avg. volume:
29.8K
1-year change:
518.18%
Market cap:
$133.8M
Revenue:
$12.4M
EPS (TTM):
-$0.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LDXHF
Lumos Diagnostics Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
CATX
Perspective Therapeutics, Inc.
|
$147K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$806.3K | -$0.04 | 272.5% | -33.67% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$28.5M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LDXHF
Lumos Diagnostics Holdings Ltd.
|
$0.1700 | -- | $133.8M | -- | $0.00 | 0% | 9.33x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.7500 | $12.3077 | $204.4M | -- | $0.00 | 0% | 186.46x |
|
PMI
Picard Medical
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
VNRX
VolitionRX Ltd.
|
$0.26 | $2.20 | $31.4M | -- | $0.00 | 0% | 17.54x |
|
VTAK
Catheter Precision, Inc.
|
$1.98 | -- | $2.4M | 0.40x | $0.00 | 0% | 9.31x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.77 | $1.50 | $107.8M | 75.49x | $0.00 | 0% | 0.84x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LDXHF
Lumos Diagnostics Holdings Ltd.
|
-- | 1.451 | -- | 0.57x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
PMI
Picard Medical
|
-- | 0.000 | -- | -- |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | -0.348 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LDXHF
Lumos Diagnostics Holdings Ltd.
|
-- | -- | -72.19% | -99.78% | -- | -- |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Lumos Diagnostics Holdings Ltd. vs. Competitors
-
Which has Higher Returns LDXHF or CATX?
Perspective Therapeutics, Inc. has a net margin of -- compared to Lumos Diagnostics Holdings Ltd.'s net margin of -12425.36%. Lumos Diagnostics Holdings Ltd.'s return on equity of -99.78% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital LDXHFLumos Diagnostics Holdings Ltd.-- -- $7.1M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About LDXHF or CATX?
Lumos Diagnostics Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 347.55%. Given that Perspective Therapeutics, Inc. has higher upside potential than Lumos Diagnostics Holdings Ltd., analysts believe Perspective Therapeutics, Inc. is more attractive than Lumos Diagnostics Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings LDXHFLumos Diagnostics Holdings Ltd.0 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is LDXHF or CATX More Risky?
Lumos Diagnostics Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock LDXHF or CATX?
Lumos Diagnostics Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lumos Diagnostics Holdings Ltd. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LDXHF or CATX?
Lumos Diagnostics Holdings Ltd. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Lumos Diagnostics Holdings Ltd.'s net income of -- is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Lumos Diagnostics Holdings Ltd.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lumos Diagnostics Holdings Ltd. is 9.33x versus 186.46x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LDXHFLumos Diagnostics Holdings Ltd.9.33x -- -- -- CATXPerspective Therapeutics, Inc.186.46x -- $209K -$26M
-
Which has Higher Returns LDXHF or PMI?
Picard Medical has a net margin of -- compared to Lumos Diagnostics Holdings Ltd.'s net margin of --. Lumos Diagnostics Holdings Ltd.'s return on equity of -99.78% beat Picard Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LDXHFLumos Diagnostics Holdings Ltd.-- -- $7.1M PMIPicard Medical-- -- -- -
What do Analysts Say About LDXHF or PMI?
Lumos Diagnostics Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Lumos Diagnostics Holdings Ltd. has higher upside potential than Picard Medical, analysts believe Lumos Diagnostics Holdings Ltd. is more attractive than Picard Medical.
Company Buy Ratings Hold Ratings Sell Ratings LDXHFLumos Diagnostics Holdings Ltd.0 0 0 PMIPicard Medical0 0 0 -
Is LDXHF or PMI More Risky?
Lumos Diagnostics Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LDXHF or PMI?
Lumos Diagnostics Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lumos Diagnostics Holdings Ltd. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LDXHF or PMI?
Lumos Diagnostics Holdings Ltd. quarterly revenues are --, which are smaller than Picard Medical quarterly revenues of --. Lumos Diagnostics Holdings Ltd.'s net income of -- is lower than Picard Medical's net income of --. Notably, Lumos Diagnostics Holdings Ltd.'s price-to-earnings ratio is -- while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lumos Diagnostics Holdings Ltd. is 9.33x versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LDXHFLumos Diagnostics Holdings Ltd.9.33x -- -- -- PMIPicard Medical-- -- -- --
-
Which has Higher Returns LDXHF or VNRX?
VolitionRX Ltd. has a net margin of -- compared to Lumos Diagnostics Holdings Ltd.'s net margin of -862.39%. Lumos Diagnostics Holdings Ltd.'s return on equity of -99.78% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LDXHFLumos Diagnostics Holdings Ltd.-- -- $7.1M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About LDXHF or VNRX?
Lumos Diagnostics Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 759.38%. Given that VolitionRX Ltd. has higher upside potential than Lumos Diagnostics Holdings Ltd., analysts believe VolitionRX Ltd. is more attractive than Lumos Diagnostics Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings LDXHFLumos Diagnostics Holdings Ltd.0 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is LDXHF or VNRX More Risky?
Lumos Diagnostics Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
-
Which is a Better Dividend Stock LDXHF or VNRX?
Lumos Diagnostics Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lumos Diagnostics Holdings Ltd. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LDXHF or VNRX?
Lumos Diagnostics Holdings Ltd. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Lumos Diagnostics Holdings Ltd.'s net income of -- is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Lumos Diagnostics Holdings Ltd.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lumos Diagnostics Holdings Ltd. is 9.33x versus 17.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LDXHFLumos Diagnostics Holdings Ltd.9.33x -- -- -- VNRXVolitionRX Ltd.17.54x -- $627.3K -$5.4M
-
Which has Higher Returns LDXHF or VTAK?
Catheter Precision, Inc. has a net margin of -- compared to Lumos Diagnostics Holdings Ltd.'s net margin of -1037.17%. Lumos Diagnostics Holdings Ltd.'s return on equity of -99.78% beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital LDXHFLumos Diagnostics Holdings Ltd.-- -- $7.1M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About LDXHF or VTAK?
Lumos Diagnostics Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1819.25%. Given that Catheter Precision, Inc. has higher upside potential than Lumos Diagnostics Holdings Ltd., analysts believe Catheter Precision, Inc. is more attractive than Lumos Diagnostics Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings LDXHFLumos Diagnostics Holdings Ltd.0 0 0 VTAKCatheter Precision, Inc.0 0 0 -
Is LDXHF or VTAK More Risky?
Lumos Diagnostics Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.
-
Which is a Better Dividend Stock LDXHF or VTAK?
Lumos Diagnostics Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lumos Diagnostics Holdings Ltd. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LDXHF or VTAK?
Lumos Diagnostics Holdings Ltd. quarterly revenues are --, which are smaller than Catheter Precision, Inc. quarterly revenues of $226K. Lumos Diagnostics Holdings Ltd.'s net income of -- is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Lumos Diagnostics Holdings Ltd.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lumos Diagnostics Holdings Ltd. is 9.33x versus 9.31x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LDXHFLumos Diagnostics Holdings Ltd.9.33x -- -- -- VTAKCatheter Precision, Inc.9.31x 0.40x $226K -$2.3M
-
Which has Higher Returns LDXHF or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -- compared to Lumos Diagnostics Holdings Ltd.'s net margin of 3.93%. Lumos Diagnostics Holdings Ltd.'s return on equity of -99.78% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital LDXHFLumos Diagnostics Holdings Ltd.-- -- $7.1M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About LDXHF or XTNT?
Lumos Diagnostics Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 94.81%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Lumos Diagnostics Holdings Ltd., analysts believe Xtant Medical Holdings, Inc. is more attractive than Lumos Diagnostics Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings LDXHFLumos Diagnostics Holdings Ltd.0 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is LDXHF or XTNT More Risky?
Lumos Diagnostics Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock LDXHF or XTNT?
Lumos Diagnostics Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lumos Diagnostics Holdings Ltd. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LDXHF or XTNT?
Lumos Diagnostics Holdings Ltd. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Lumos Diagnostics Holdings Ltd.'s net income of -- is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Lumos Diagnostics Holdings Ltd.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 75.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lumos Diagnostics Holdings Ltd. is 9.33x versus 0.84x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LDXHFLumos Diagnostics Holdings Ltd.9.33x -- -- -- XTNTXtant Medical Holdings, Inc.0.84x 75.49x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
